

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI133281

| | |
|---|---------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| IsoTherapeutics Group, LLC | 03/27/2024 |
| RECEIVING PARTY DATA | |
| Company Name: | IGL Pharma, Inc. |
| Street Address: | 213 Pansy Path |
| City: | Lake Jackson |
| State/Country: | TEXAS |
| Postal Code: | 77566 |
| PROPERTY NUMBERS Total: 6 | |
| Property Type | Number |
| PCT Number: | US1271256 |
| Patent Number: | 9687574 |
| Patent Number: | 10583211 |
| Patent Number: | 10918746 |
| Application Number: | 61606734 |
| Application Number: | 61578630 |
| CORRESPONDENCE DATA | |
| Fax Number: | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 9898593085 |
| Email: | techlaw@tm.net |
| Correspondent Name: | Karen L Kimble |
| Address Line 1: | 2745 First Street, 503 |
| Address Line 4: | Fort Myers, FLORIDA 33916 |
| ATTORNEY DOCKET NUMBER: | ITG-15 US |
| NAME OF SUBMITTER: | Karen Kimble |
| SIGNATURE: | Karen Kimble |
| DATE SIGNED: | 03/30/2024 |
| Total Attachments: 4 | |

source=Patent Assignment ITG-15 2024-03-27#page1.tif

source=Patent Assignment ITG-15 2024-03-27#page2.tif

source=Patent Assignment ITG-15 2024-03-27#page3.tif

source=Patent Assignment ITG-15 2024-03-27#page4.tif

PATENT

REEL: 067098 FRAME: 0839

PATENT ASSIGNMENT

This Patent Assignment (this "Assignment") is made and entered into as of March 26, 2024, by and between **IsoTherapeutics Group, LLC**, a Texas limited liability company having an address of 1004 S. Velasco Street, Angleton, TX 77515 ("Assignor"), and **IGL Pharma, Inc.**, a Delaware corporation having an address of 213 Pansy Path, Lake Jackson, TX 77566 ("Assignee").

In consideration of the payment of One Dollar (\$1.00) and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor and Assignee agree as follows:

1. Assignment. Assignor hereby sells, assigns, grants, conveys, transfers, and delivers to Assignee, its successors and assigns, and Assignee hereby assumes, all of Assignor's right, title, benefit, privilege, and interest in, to and under:

(a) each patent identified in Exhibit A to this Assignment, and all inventions disclosed or claimed, in whole or in part, in the same, and including the relevant technology to enable the implementation of the invention (the "Inventions");

(b) all patents and patent applications that have been or may later be filed that are based on any Invention in any country, including any provisional, non-provisional, divisional, continuation, continuation-in-part, extension, renewal, re-examination, reissue, substitute, supplementary protection certificate, utility model, or similar legal protection based on any of the Inventions (collectively, and together with the patents identified in Exhibit A, the "Patents");

(c) the right to claim priority to any of the Patents under the patent laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or laws of the country in which the Patents are filed, as may be applicable; and

(d) all rights of action, powers, and benefits arising from ownership of the Patents, including the right to sue for past, present, and future infringement of the Patents, the right to collect royalties, fees, damages, and payments now or later due or payable with respect to the Patents, the right to seek injunctive relief based on the Patents, and the right to pursue all causes of action and all enforcement rights relating to the Patents, whether known or unknown, currently pending or otherwise.

The rights assigned in (a)-(d) above are referred to collectively in this Assignment as the "Assigned Rights."

2. Communications. Assignee is authorized to communicate with the United States Patent and Trademark Office (and corresponding offices or agencies in other countries of the world) with respect to the Assigned Rights, and the United States Patent and Trademark Office (and corresponding offices or agencies in other countries of the world) is authorized to receive and act upon all instructions, communications, correspondence, or other information sent or provided by Assignee with respect to the Assigned Rights to the same extent as if this Assignment had not been made and such instructions, communications, correspondence, or other information had been received from Assignor.

3. Parties Bound. This Assignment shall be binding upon and inure to the benefit of Assignor and Assignee and their respective successors and permitted assigns.

4. Applicable Law. This Assignment shall be governed by and construed and enforced in accordance

with the internal laws of the State of Delaware without giving effect to the principles of conflicts of law thereof.

5. Counterparts. This Assignment may be executed in counterparts and delivered by facsimile, portable document format (.pdf) transmission or other electronic format, each of which shall be deemed an original, and all of which taken together shall constitute one and the same assignment.

6. Global. This Assignment is deemed to be global with respect to all Patents and is consented to with that understanding.

[Remainder of Page Intentionally Left Blank -- Signatures and Acknowledgements to Follow]

IN WITNESS WHEREOF, this Patent Assignment has been duly executed and authorized, effective as of the date first above written.

ASSIGNOR:

IsoTherapeutics Group, LLC
a Texas limited liability company

By: R. Keith Frank

Name: R. Keith Frank
Title: President & CEO

ASSIGNEE:

IGL Pharma, Inc.
a Delaware corporation

By: R. Keith Frank

Name: R. Keith Frank
Title: President & CEO

STATE OF TEXAS)
)ss
COUNTY OF BRAZORIA)

On this 21st day of March 2024, before me, the undersigned, a Notary Public within and for said County and State, personally appeared R. Keith Frank, President & CEO of IsoTherapeutics Group, LLC, a Texas limited liability company, to me known to be the person who executed the foregoing instrument, and acknowledged that he executed the same on behalf of said company as such company's free act and deed.


In Witness Whereof, I have hereunto attached my hand and notarial seal, at the County and State aforesaid on the day and year last above written.

Kimberly Miller
Notary Public

My Commission Expires:

01-13-2028

STATE OF TEXAS)
)ss
COUNTY OF BRAZORIA)



On this 21st day of March 2024, before me, the undersigned, a Notary Public within and for said County and State, personally appeared R. Keith Frank, President & CEO of IGL Pharma, Inc., a Delaware corporation, to me known to be the person who executed the foregoing instrument, and acknowledged that he executed the same on behalf of said corporation as such corporation's free act and deed.

In Witness Whereof, I have hereunto attached my hand and notarial seal, at the County and State aforesaid on the day and year last above written.

Kimberly Miller
Notary Public

My Commission Expires:

01-13-2028




Exhibit A**Patents**

| Country | Serial No / Filing Date | Publication No / Publication Date | Patent No / Issue Date |
|---|------------------------------------|--|-----------------------------------|
| Australia (AU) | 2012358364 21-Dec-2012 | 2793955 29-Oct-2014 | 2012358364 23-Nov-2017 |
| Canada (CA) | 2859971 21-Dec-2012 | 2859971 27-Jun-2013 | 2859971 4-Aug-2020 |
| EP: United Kingdom (UK) France (FR) Germany (DE) Italy (IT) Netherlands (NL) Spain (ES) Switzerland (CH) Belgium (BE) Czech Republic CZ) | 12860525.0 21-Dec -2012 | 2793955 29-Oct-2014 | 2793955 11-Apr-2018 |
| Japan | 2014-548954 21-Dec-2012 | 2015510496 9-Apr-2015 | 6219841 6-Oct-2017 |
| Japan (DIV) | 2017-047326 12-Apr-2017 | 2017-149722 31-Aug-2017 | 6356854 22-Jun-2018 |
| Korea | 10-2014-7019820 21-Dec-2012 | 1020140105016 29-Aug-2014 | 10-1973830 29-Apr-2019 |
| Korea (DIV) | 10-2019-7011613 22-Apr-2019 | 1020190047101 7-May-2019 | 10-2006599 1-Aug-2019 |
| PCT | PCT/US2012/071256 21-Dec-12 | WO 2013/096776 27-Jun-13 | n/a |
| US | 14/367,758 21-Dec-2012 | US2015-0023869 22-Jan-2015 | 9,687,574 27-Jun-2017 |
| US (DIV) | 15/600,184 19-May-2017 | US2017-0258949 14-Sep-2017 | 10,583,211 10-Mar-2020 |
| US (DIV) | 16/773,398 27-Jan-2020 | US2020-0155716 21-May-2020 | 10,918,746 16-Feb-2021 |
| US (PROV) | 61/578,630 21-Dec-2011 | n/a | n/a |
| US (PROV) | 61/606,734 5-Mar-2012 | n/a | n/a |